Is Afzanna 30mg tablet chemotherapy or targeted therapy?

Afzanna 30mg tablet is targeted therapy which directly focuses on the cancer cells to kill them and prevent the body from further growing cancer in the body.

How can I take Afzanna tablet?

The duration and dosage of Afzanna 30mg is depend on the patient medical history and prescription of a doctor. Consult the healthcare expert to know the complete information about the medication.

What side effects Afzanna 30mg tablet show?

Afzanna treats lung cancer, but some patient may experience side effects such as Itching, headache, loss of appetite and many more. Consult the doctor about the symptoms and follow the dosage as recommended by the healthcare expert.

How long should I take Afzanna 30mg tablet?

Afzanna 30mg tablet is taken as long as the doctor prescribed, do not stop or skip the dosage without consulting the doctor.

Buy Afzanna 30mg Tablet Online: Price, 48% Discount, Uses, and Side Effects

Name: Afzanna 30mg Tablet
Brand: Afzanna
Price: 4050 INR
Availability: InStock
Rating: 4.43 (7 reviews)

Description

Afzanna 30mg tablet is a targeted based therapy designed to specifically attack cancer cells with EGFR mutations, helping to slow or stop their growth and multiplication. This anti-cancer medication is used treat non-small cell lung cancer, its active ingredients is Afatinib, present in its salt form.

The medication should be taken according to the doctor to ensure maximum effectiveness and safety. It is not used alone and not in combination with other medication, as it is prescribed as a monotherapy.

Afzanna 30mg tablet is strictly prescribed by the healthcare provider.

Indication

Non small cell lung cancer

Common side effects

Afzanna 30mg tablet has various side effects like any other medication has.
Some of the patients do not experience any symptoms but some need proper treatment to recover.
Visit the doctor instantly if the symptoms persist: ● Diarrhea ● Rash ● Dry skin ● Vomiting ● Itching ● Nail disorder ● Nausea ● Loss of appetite ● Stomatitis ● Headache

Dosage and duration

Afzanna tablet is highly recommended to lung cancer patients which can be taken on an empty stomach at the same time everyday.
Do not chew, crush just swallow the whole tablet at once.
Guidance from the healthcare expert is much needed to ensure safety and enhance the effectiveness of the medication.
Never skip or double the dose to make up for the missed one, as this may increase the risk of side effects.

Mechanism of action

Lung cancer contain EGFR gene which cause abnormal cell growth and uncontrolled multiplication of cancer cells in the body. Afzanna 30mg tablet block endothelial growth factor receptor, which is responsible for the growth and multiplication of cancer cells in the body.

The medication is targeted therapy which directly targets the tumor growth but does not damage the healthy cells that increase the effectiveness of the treatment.

Safety advice

Alcohol

Avoid using alcohol while using Afzanna 30mg tablet, as it affect the treatment effectiveness.

Driving

Afzanna 30mg does not affect driving mode, but if you experience any harmful symptoms then consult the doctor and follow the guidance as recommended.

Pregnancy

Pregnant women should avoid using Afzanna 30mg capsule because the medication contain hard substances which affect the fetus in various ways. It is better to consult with the doctor before using the medication.

Breast Feeding

Afzanna 30mg tablet is not recommended to women who breastfeed their child as the medication is passed through breast which harm the baby.

Kidney

Afzanna 30mg tablet is not recommended for kidney patients as the medicine can interrupt the kidney function and produce complications in the treatment.

Liver

The liver plays an important role in the body, Afzanna 30mg tablet is not recommended to liver patients because it may harm the liver in many ways.

FAQs

Afzanna 30mg tablet is taken by non small cell lung cancer by blocking the epidermal growth factor receptor.

The medicine stops the growth and progression of cancer cells in the body.

Reference

• Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., ... & Paz-Ares, L.

(2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

The Lancet Oncology, 17(5), 577-589. • Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., ... & Adolf, G. R.

(2012). Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

The Journal of pharmacology and experimental therapeutics, 343(2), 342-350. • Harvey, R. D., Adams, V.

R., Beardslee, T., & Medina, P. (2020).

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 26(6), 1461-1474. • Schuler, M., Yang, J.

H., Park, K., Kim, J. H., Bennouna, J., Chen, Y.

M., ... & Popovych, O. (2016).

Afatinib beyond progressio • Yang, J. C.

H., Shih, J. Y., Su, W.

C., Hsia, T. C., Tsai, C.

M., Ou, S. H.

I., ... & Miller, V. A.

(2012). Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

The lancet oncology, 13(5), 539-548.

Afzanna 30mg Tablet

About The Product